Related Experiment Video
Updated: Mar 17, 2026
07:30
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
9.8K
Paliperidone Induced Hypoglycemia by Increasing Insulin Secretion
Tsubasa Omi1, Keisen Riku1, Motoyuki Fukumoto1
1Department of Psychiatry, Osaka General Medical Center, 3-1-56 Bandai-higashi, Sumiyoshi, Osaka 5588558, Japan.
Case Reports in Psychiatry
|August 2, 2016
Summary
Paliperidone, an antipsychotic, may cause persistent hypoglycemia by increasing insulin secretion. This can mask underlying diabetes symptoms, highlighting the need to monitor glucose metabolism with atypical antipsychotic use.
Area of Science:
- Endocrinology
- Pharmacology
- Psychiatry
Background:
- Schizophrenia is a chronic mental disorder often treated with atypical antipsychotics.
- Atypical antipsychotics, including paliperidone, are associated with metabolic side effects.
- Glucose metabolism disturbances are a known concern with these medications.
Purpose of the Study:
- To report a case of persistent hypoglycemia associated with paliperidone use in a patient with schizophrenia.
- To investigate the potential of paliperidone-induced hypoglycemia to mask diabetes symptoms.
- To explore the mechanism of paliperidone's effect on glucose metabolism.
Main Methods:
- Case report of a 41-year-old woman with schizophrenia.
- Administration and subsequent discontinuation of paliperidone.
- Monitoring of blood glucose levels and clinical symptoms.
Main Results:
- The patient developed persistent hypoglycemia after starting paliperidone.
- Hypoglycemia resolved upon paliperidone discontinuation.
- Emergence of diabetes symptoms after paliperidone withdrawal.
Conclusions:
- Paliperidone may induce hypoglycemia, potentially masking the diagnosis of diabetes.
- The mechanism may involve increased insulin secretion.
- This case underscores the importance of monitoring glucose metabolism in patients receiving paliperidone and other atypical antipsychotics.
Related Concept Videos
01:06Oral Hypoglycemic Agents: Glinides
837
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
837
01:23Dipeptidyl Peptidase 4 Inhibitors
895
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
895
01:15Hypoglycemia and Glucagon
1.2K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.2K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
830
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
830
01:24Glucagon-like Receptor Agonists
1.2K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.2K
01:16Insulin: Dosing Regimen and Adverse Effects
1.1K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.1K